Phase II Study of RAD001 [everolimus] Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell).
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2012
At a glance
- Drugs Everolimus; Octreotide
- Indications Neuroendocrine carcinoma
- Focus Biomarker; Therapeutic Use
- 06 Dec 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 06 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Nov 2006 Status change